Reuters logo
AstraZeneca boosts lung drug business with up to $2.1 bln Almirall deal
July 30, 2014 / 6:20 AM / 3 years ago

AstraZeneca boosts lung drug business with up to $2.1 bln Almirall deal

LONDON, July 30 (Reuters) - AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion to acquire the rights to lung drugs developed by Spain’s Almirall.

The British drugmaker, which resisted a $118 billion takeover attempt by Pfizer in May, said it would pay an initial $875 million and up to $1.22 billion in development, launch and sales-related milestones for access to Almirall’s existing and pipeline respiratory drugs. (Reporting by Ben Hirschler; editing by Keith Weir)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below